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England and Wales, 1971–2011: a population-based study
Manuela Quaresma, Michel P Coleman, Bernard Rachet
Summary
Background Assessment of progress in cancer control at the population level is increasingly important. 
Population-based survival trends provide a key insight into the overall eﬀ ectiveness of the health system, alongside 
trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival.
Methods In this observational study, we analysed trends in survival with population-based data for 7·2 million adults 
diagnosed with a ﬁ rst, primary, invasive malignancy in England and Wales during 1971–2011 and followed up to the 
end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry 
and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the 
age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed 
trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971–72, 1980–81, 
1990–91, 2000–01, 2005–06, and 2010–11. We also estimated trends in age-sex-adjusted survival for each cancer. We 
deﬁ ne the diﬀ erence in net survival between the oldest (75–99 years) and youngest (15–44 years) patients as the age 
gap in survival. We evaluated the absolute change (%) in the age gap since 1971.
Findings The overall index of net survival increased substantially during the 40-year period 1971–2011, both in England 
and in Wales. For patients diagnosed in 1971–72, the index of net survival was 50% at 1 year after diagnosis. 40 years 
later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women 
persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed 
between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the 
oldest patients (75–99 years) was persistently lower than for the youngest (15–44 years), even after adjustment for the 
much higher mortality from causes other than cancer in elderly people.
Interpretation These ﬁ ndings support substantial increases in both short-term and long-term net survival from all 
cancers combined in both England and Wales. The net survival index provides a convenient, single number that 
summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old 
men and women and for a wide range of cancers with very disparate survival. The persistent sex diﬀ erence is partly 
due to a more favourable cancer distribution in women than men. The very wide diﬀ erences in survival for diﬀ erent 
cancers, and the persistent age gap in survival, suggest the need for renewed eﬀ orts to improve cancer outcomes. 
Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about 
sharing of individual data for public health research can be resolved.
Funding Cancer Research UK.
Copyright © Quaresma et al. Open Access article distributed under the terms of CC BY.
Introduction
Cancer is an increasing public health concern, shown by 
substantial investments in human and ﬁ nancial 
resources for cancer management since the late 1990s. 
Health policy measures have focused on improvement of 
the organisation and delivery of services for prevention, 
diagnosis, and treatment. Research has provided the 
evidence base for these policies and is increasingly used 
to assess their eﬀ ect.1–7 The assessment of progress in 
cancer control has become crucial. Population-based 
cancer survival trends provide a key insight into the 
overall eﬀ ectiveness of the health system, alongside 
incidence and mortality.8
In this population-based survival study, we analysed 
cancer survival trends during the past four decades in 
England and Wales using two metrics: an index of 
survival for all cancers combined, and survival for each 
cancer, adjusted for age and sex. The all-cancers survival 
index was designed to provide one summary measure 
of cancer survival that can be monitored over time to 
show the overall progress in the eﬀ ectiveness of the 
health-care system. It was also designed to support 
assessment of the eﬀ ect of earlier diagnosis, which is a 
key component of the National Awareness and Early 
Diagnosis Initiative.9–11 Trends in survival for individual 
cancers will underline those cancer types for which 
Lancet 2015; 385: 1206–18
Published Online
December 3, 2014
http://dx.doi.org/10.1016/
S0140-6736(14)61396-9
This online publication has been 
corrected. The corrected version 
ﬁ rst appeared at thelancet.com 
on March 27, 2015
See Comment page 1162
Cancer Research UK Cancer 
Survival Group, Department of 
Non-Communicable Disease 
Epidemiology, London School 
of Hygiene & Tropical Medicine, 
London, UK 
(M Quaresma Licenciatura, 
Prof M P Coleman FFPH, 
B Rachet FFPH) 
Correspondence to:
Ms Manuela Quaresma, 
Department of Non-
Communicable Disease 
Epidemiology, Faculty of 
Epidemiology and Population 
Health, London School of 
Hygiene & Tropical Medicine, 
London WC1E 7HT, UK
manuela.quaresma@lshtm.
ac.uk
Articles
www.thelancet.com   Vol 385   March 28, 2015 1207
there has been progress and those for which prognosis 
has remained poor.
Methods
Study design
Survival varies very widely with the age and sex of a 
patient with cancer and with the type of cancer. The 
frequency of diﬀ erent cancers is also changing over time: 
some cancers with poor prognosis, such as stomach and 
lung cancer, have become less common, whereas breast 
cancer in women, for which survival has been improving, 
has become more common. These trends can diﬀ er 
between the sexes: lung cancer has become much less 
common in men, but more common in women. The age 
proﬁ le of patients with cancer also changes over time, 
and these trends can diﬀ er between cancers. To enable 
valid assessment of survival trends for all cancers 
combined, the survival index must therefore take account 
of changes over time in the distribution of age, sex, and 
cancer type in all patients with cancer, especially over 
periods as long as 40 years. Similarly, trends in survival 
for each cancer must be adjusted for changes over time 
in the age (and sex) proﬁ le of patients with cancer.
Data sources
We examined survival trends in 7 176 795 adults (aged 
15–99 years) diagnosed with a ﬁ rst, primary, invasive 
malignancy in England and Wales during 1971–2011, and 
followed up to Dec 31, 2012 (table 1). Data for England 
were obtained from the National Cancer Registry at the 
Oﬃ  ce for National Statistics12 and for Wales from the 
Welsh Cancer Intelligence and Surveillance Unit. Patients 
diagnosed with a malignancy of the skin other than 
melanoma were excluded. Since 1971, the National Health 
Service Central Register has routinely updated these 
individual cancer records with information about each 
patient’s vital status (alive, emigrated, dead, or not traced). 
The vital status at Dec 31, 2012, was known for 98·4% of 
these patients. During the 41-year period, 4·3% of all 
cancer registrations were for the patient’s second-order or 
higher-order tumour: in the analyses for all cancers 
combined, the higher-order cancers were not included.
Statistical analysis
The all-cancers survival index was constructed as a 
weighted average of the survival estimates for every 
combination of age group at diagnosis (15–44, 45–54, 
ICD-10 code* England Wales
Women Men Women Men
Number % Number % Number % Number %
Oesophagus C15 67 474 2·0% 106 793 3·1% 4953 2·3% 6857 3·1%
Stomach C16 115 294 3·4% 194 333 5·7% 8627 4·0% 14 299 6·5%
Colon C18 292 352 8·7% 271 220 8·0% 17 711 8·3% 17 736 8·1%
Rectum C19–C21 143 610 4·3% 204 363 6·0% 9731 4·5% 14 358 6·6%
Pancreas C25 92 631 2·8% 93 450 2·7% 5868 2·7% 6014 2·7%
Larynx (men) C32 ·· ·· 52 618 1·5% ·· ·· 3529 1·6%
Lung C33, C34 349 711 10·5% 751 958 22·1% 21 027 9·8% 45 601 20·8%
Melanoma C43 97 627 2·9% 72 743 2·1% 5429 2·5% 4372 2·0%
Breast (women) C50 1 039 609 31·1% ·· ·· 65 370 30·6% ·· ··
Cervix C53 117 404 3·5% ·· ·· 8272 3·9% ·· ··
Uterus C54, C55 160 539 4·8% ·· ·· 10 836 5·1% ·· ··
Ovary C56, C57.0–7 172 400 5·2% ·· ·· 11 051 5·2% ·· ··
Prostate C61 ·· ·· 638 111 18·8% ·· ·· 41 559 19·0%
Testis C62 ·· ·· 48 031 1·4% ·· ·· 2743 1·3%
Kidney C64–C66, C68 53 197 1·6% 89 986 2·6% 3431 1·6% 5804 2·6%
Bladder C67 90 204 2·7% 239 621 7·0% 5897 2·8% 15 962 7·3%
Brain C71 41 952 1·3% 59 192 1·7% 2832 1·3% 3786 1·7%
Hodgkin’s disease C81 19 114 0·6% 26 714 0·8% 1145 0·5% 1675 0·8%
Non-Hodgkin lymphoma C82–C85 99 752 3·0% 114 269 3·4% 5630 2·6% 6320 2·9%
Myeloma C90 43 446 1·3% 48 136 1·4% 2805 1·3% 3041 1·4%
Leukaemia C91–C95 70 760 2·1% 92 917 2·7% 4686 2·2% 6112 2·8%
Other cancers† ·· 275 408 8·2% 296 794 8·7% 18 624 8·7% 19 369 8·8%
Total ·· 3 342 484 100·0% 3 401 249 100·0% 213 925 100·0% 219 137 100·0%
*Tenth revision of the International Classiﬁ cation of Diseases (ICD): malignancies were initially coded according to the ICD revision in use during the year of diagnosis—ie, ICD 
8 (1971–78), 9 (1979–95), or 10 (1996–). †Other cancers: all other malignant tumours are combined; they also include laryngeal cancer in women and breast cancer in men.
Table 1: Number of patients (aged 15–99 years) included in analyses in England and Wales diagnosed from 1971 to 2011 and followed up to 2012, by 
sex and type of malignancy
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55–64, 65–74, and 75–99 years), sex (male and female), and 
type of cancer (the 21 most common malignancies are 
shown in table 1 and all other malignant tumours are 
combined). The weights used were the proportion of 
patients with cancer diagnosed in England and Wales 
during 1996–99 in each of the 185 combinations of age 
group, sex, and type of cancer. We also constructed the all-
cancers survival index separately for males and females 
and estimated survival adjusted for age and sex by cancer.
Net survival was used as the cancer survival measure 
for each component of the indexes. Net survival 
quantiﬁ es the survival after taking account of death from 
other causes (background mortality). All patients were 
allocated a deprivation category deﬁ ned according to 
their Lower Super Output Area (mean population about 
1500) of residence at the time of cancer diagnosis. Life-
tables were used to take account of the wide variation in 
background mortality by age, sex, deprivation, region, 
and over time. For this study, separate life-tables were 
created for England and Wales by single year of age, sex, 
deprivation category, and (in England) region of 
residence, for every calendar year between 1971 and 
2012.13 National or regional life-tables were used for the 
2·8% of patients diagnosed in England (2·6% in Wales) 
who could not be assigned to a speciﬁ c deprivation 
category or (in England) region; almost all of these 
patients were diagnosed in the 1970s (85% in England, 
55% in Wales) or 1980s (14% England, 44% Wales).
We used ﬂ exible multivariable parametric excess 
hazard models14,15 to estimate net survival up to 10 years 
after diagnosis for each nation, and for each stratum 
deﬁ ned by cancer, sex, age group, and calendar period. 
The models included age and year of diagnosis as main 
eﬀ ects, modelled on a continuous scale with restricted 
cubic splines, to account for potential non-linear excess 
(cancer-related) hazards. Interactions between age and 
year of diagnosis, year of diagnosis and follow-up time, 
and age and follow-up time were assessed to deal with 
potential variation of the excess hazard with time since 
diagnosis. The best-ﬁ tting models were chosen as those 
with the smallest Akaike Information Criterion.16 Net 
survival curves were estimated for each individual from 
these models according to their age and year of diagnosis. 
We obtained net survival estimates for each cancer and 
sex by averaging of individual net survival curves, over all 
ages and years of diagnosis within each age group and 
calendar period. In view of the fact that the models 
included the year of diagnosis as a continuous variable, 
we were able to predict survival up to 10 years after 
diagnosis, even for the patients diagnosed most recently 
(ie, 2010–11). All models were ﬁ tted with the STATA 
command stpm2 using STATA 13.1.17,18
We included all patients diagnosed during the 
40 years from 1971 to 2011 in the models to estimate 
survival trends, but we report estimates for each cancer 
survival index at 1, 5, and 10 years after diagnosis only 
for six selected periods of diagnosis: 1971–72, 1980–81, 
1990–91, 2000–01, 2005–06, and 2010–11. We deﬁ ne the 
diﬀ erence in net survival between the oldest 
(75–99 years) and youngest (15–44 years) groups as the 
age gap in survival. We provide a simple summary of 
changes in survival by age as the absolute change (%) in 
the age gap since 1971. A negative value for this change 
means that the age gap has become wider. For Wales, 
reliable estimates of net survival could not be obtained 
for 11·5% of the age-sex-cancer combinations because 
Figure 1: Trends in the index of net survival for all cancers combined, for England and for Wales: all adults 
(15–99 years), men, and women, selected periods during 1971–2011
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1971–72 1980–81 1990–91 2000–01 2005–06 2010–11 (prediction)
1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years
All cancers com bined
All patients 50·1% 29·8% 24·0% 55·8% 35·3% 28·8% 60·6% 41·0% 34·4% 64·9% 47·4% 41·6% 67·6% 50·9% 45·8% 70·5% 54·3% 49·8%
Men 44·7% 25·2% 19·9% 50·6% 29·6% 23·3% 55·7% 34·8% 28·0% 60·7% 42·0% 36·0% 63·7% 45·8% 41·0% 66·7% 49·2% 45·7%
Women 55·5% 34·3% 27·9% 61·0% 40·9% 34·1% 65·3% 47·2% 40·7% 69·0% 52·7% 47·0% 71·5% 56·0% 50·5% 74·2% 59·2% 53·8%
Oeso phagus
All patients 15·0% 4·3% 3·5% 19·1% 5·3% 4·3% 24·2% 6·5% 5·1% 31·1% 8·8% 7·0% 36·4% 11·5% 9·3% 42·0% 15·3% 12·4%
Men 14·7% 4·0% 3·3% 18·5% 4·8% 3·8% 24·1% 6·1% 4·8% 32·5% 9·1% 7·3% 38·3% 12·0% 9·4% 44·3% 15·6% 12·0%
Women 15·6% 4·8% 3·9% 20·0% 6·2% 5·0% 24·3% 7·1% 5·6% 28·8% 8·2% 6·5% 33·4% 10·8% 9·1% 38·6% 14·7% 13·1%
Stomach
All patients 15·4% 5·2% 4·0% 20·6% 8·2% 6·7% 26·8% 10·9% 8·9% 33·9% 14·1% 11·3% 37·8% 16·3% 13·1% 41·7% 18·8% 15·0%
Men 15·3% 5·2% 4·0% 20·7% 8·1% 6·7% 27·0% 10·6% 8·6% 34·7% 13·9% 11·0% 39·3% 16·5% 13·0% 43·8% 19·5% 15·3%
Women 15·5% 5·3% 4·0% 20·5% 8·4% 6·8% 26·5% 11·5% 9·4% 32·4% 14·5% 11·8% 35·2% 16·1% 13·1% 37·9% 17·7% 14·4%
Colon
All patients 41·5% 24·6% 22·8% 54·0% 34·2% 31·8% 62·1% 41·6% 38·6% 66·7% 47·5% 44·5% 70·3% 52·6% 50·3% 73·9% 58·2% 56·9%
Men 42·6% 25·3% 23·0% 55·2% 34·6% 31·5% 63·5% 41·9% 38·1% 68·1% 47·6% 43·6% 71·9% 52·9 49·4% 76·1% 59·2% 56·5%
Women 40·4% 23·8% 22·6% 52·7% 33·8% 32·1% 60·7% 41·3% 39·0% 65·4% 47·5% 45·4% 68·6% 52·3% 51·1% 71·7% 57·3% 57·4%
Rectum
All patients 53·3% 24·2% 20·1% 60·6% 32·5% 28·2% 67·8% 42·0% 37·7% 74·0% 51·2% 47·1% 76·7% 55·5% 51·7% 79·2% 59·7% 56·1%
Men 54·1% 23·6% 19·1% 61·4% 32·0% 27·1% 68·7% 41·7% 36·7% 74·8% 51·0% 46·4% 77·5% 55·4% 51·0% 79·9% 59·6% 55·5%
Women 52·2% 25·0% 21·6% 59·5% 33·2% 29·6% 66·6% 42·4% 39·0% 72·8% 51·4% 48·2% 75·6% 55·7% 52·7% 78·1% 59·8% 57·0%
Pancreas
All patients 10·6% 2·3% 1·2% 12·1% 2·8% 1·5% 13·0% 2·8% 1·5% 14·7% 2·7% 1·2% 17·4% 3·0% 1·2% 20·9% 3·3% 1·1%
Men 10·2% 2·4% 1·3% 12·4% 3·1% 1·7% 13·5% 3·2% 1·7% 15·3% 3·0% 1·4% 18·1% 3·2% 1·2% 21·7% 3·6% 1·1%
Women 11·0% 2·2% 1·1% 11·9% 2·4% 1·2% 12·5% 2·4% 1·3% 14·0% 2·4% 1·1% 16·7% 2·7% 1·2% 20·2% 3·1% 1·1%
Larynx
Men 80·7% 60·2% 50·4% 81·7% 62·1% 52·6% 82·8% 64·1% 54·9% 83·7% 66·0% 57·0% 84·2% 67·0% 58·2% 84·7% 67·9% 59·2%
Lung
All patients 16·0% 4·6% 3·1% 18·3% 5·5% 3·7% 20·5% 6·0% 3·8% 24·4% 6·9% 4·0% 28·0% 8·0% 4·4% 32·2% 9·6% 5·0%
Men 16·3% 4·8% 3·2% 18·6% 5·8% 3·9% 20·4% 6·1% 3·9% 23·9% 6·6% 3·7% 27·0% 7·4% 3·8% 30·5% 8·4% 4·0%
Women 15·4% 4·3% 2·9% 17·8% 5·0% 3·2% 20·7% 5·9% 3·7% 25·2% 7·4% 4·5% 29·7% 9·1% 5·4% 35·1% 11·6% 6·6%
Me lanoma of skin
All patients 81·6% 52·3% 46·4% 88·7% 66·4% 60·4% 93·1% 77·2% 71·9% 95·5% 83·8% 79·7% 96·4% 87·0% 84·4% 97·4% 90·4% 89·8%
Men 74·5% 40·5% 34·9% 84·5% 56·4% 49·8% 90·8% 69·8% 63·4% 94·0% 78·4% 73·3% 95·2% 82·6% 79·3% 96·6% 87·8% 86·8%
Women 86·7% 61·1% 54·9% 91·8% 73·7% 68·3% 94·9% 82·6% 78·2% 96·6% 87·8% 84·5% 97·3% 90·2% 88·3% 97·9% 92·4% 92·1%
Breast
Women 81·9% 52·7% 40·1% 85·9% 61·2% 48·4% 89·5% 71·1% 60·0% 92·7% 80·2% 71·6% 94·5% 83·9% 75·6% 96·0% 86·7% 78·5%
Cervix
Women 74·0% 51·3% 46·0% 78·6% 58·3% 52·4% 81·6% 62·6% 57·2% 82·8% 65·4% 60·7% 82·6% 66·3% 61·9% 82·9% 67·5% 63·1%
Uterus
Women 75·6% 59·0% 55·5% 79·5% 65·1% 61·5% 83·3% 69·5% 65·6% 86·9% 73·1% 69·7% 88·7% 75·9% 73·3% 90·3% 78·8% 77·4%
Ovary
Women 43·7% 20·5% 17·9% 50·2% 24·9% 21·5% 57·0% 30·8% 26·4% 64·7% 38·4% 31·7% 68·8% 42·4% 33·5% 72·7% 46·4% 34·8%
Prostate
Men 66·1% 36·9% 25·1% 71·5% 38·2% 24·4% 79·6% 49·6% 34·1% 89·5% 73·8% 62·4% 92·4% 81·4% 75·1% 94·0% 84·8% 83·6%
Testis
Men 83·3% 70·5% 69·2% 91·2% 84·0% 83·3% 95·8% 92·3% 91·9% 98·0% 96·3% 96·2% 98·7% 97·5% 97·4% 99·1% 98·3% 98·2%
Kidney
All patients 44·9% 28·5% 23·0% 51·3% 34·1% 27·6% 57·1% 39·4% 32·3% 62·8% 44·8% 37·9% 67·2% 49·8% 43·0% 72·5% 56·3% 49·6%
Men 45·4% 28·9% 23·0% 52·6% 35·3% 28·5% 58·7% 40·8% 33·4% 63·9% 45·2% 37·8% 68·0% 50·0% 42·9% 73·2% 56·7% 50·0%
Women 43·9% 28·0% 23·1% 49·1% 32·2% 26·1% 54·4% 37·1% 30·5% 60·9% 44·0% 38·0% 65·9% 49·4% 43·2% 71·3% 55·6% 48·9%
(Table 2 continues on next page)
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of the small number of patients, and broader age 
groups were constructed to re-estimate survival for 
those combinations.
Role of the funding source
The funder had no role in study design, quality control, 
analysis, interpretation of the results, drafting, or the 
decision to submit for publication. The corresponding 
author had full access to all data and was responsible for 
the decision to publish.
Results
The index of net survival for all cancers combined at 1, 5, 
and 10 years since diagnosis increased substantially 
between 1971 and 2011 in England and Wales (ﬁ gure 1, 
tables 2 and 3). The all-cancers survival index was 50% at 
1 year after diagnosis for patients diagnosed in 1971–72. 
For patients diagnosed during 2005–06, the index was 
50% at 5 years after diagnosis, and for patients diagnosed 
during 2010–11, we predict that the all-cancers survival 
index will reach 50% at 10 years after diagnosis.
For patients diagnosed during 2010–11, the survival 
index for all cancers combined had reached 69–70% at 
1 year and a predicted value of 54% at 5 years for both sexes 
combined. The 5-year survival index rose by 24% (from 
30% to 54%) and the 10-year survival index by 26% (from 
24% to 50%) between the periods 1971–72 and 2010–11. 
Most of the increase occurred between 1990 and 2011.
The survival index for all cancers combined is 
on average 10% higher for women than for men at each 
time interval since diagnosis. The pattern of increase in 
the index was fairly similar for both men and women 
during the whole period, although the increase was 
linear for women but it became steeper for men after 
1990–91. For patients diagnosed during 2010–11, the all-
cancers survival index for women in England was 74% at 
1 year, 59% at 5 years, and 54% at 10 years, whereas the 
ﬁ gures for men were 67% at 1 year, 49% at 5 years, and 
1971–72 1980–81 1990–91 2000–01 2005–06 2010–11 (prediction)
1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years
(Continued from previous page)
Bladder
All patients 60·2% 39·3% 32·4% 73·4% 56·0% 48·0% 77·2% 60·8% 52·8% 74·7% 56·4% 49·5% 73·5% 54·8% 49·2% 72·4% 53·4% 49·5%
Men 62·8% 40·9% 33·7% 76·0% 57·9% 49·3% 80·1% 63·0% 54·2% 78·5% 59·2% 52·0% 77·6% 57·8% 52·4% 76·6% 56·5% 53·5%
Women 53·4% 35·2% 29·0% 66·6% 50·8% 44·7% 69·6% 54·9% 49·0% 64·7% 49·1% 43·0% 63·0% 47·0% 40·9% 61·4% 45·3% 39·1%
Brain
All patients 17·7% 7·2% 5·4% 23·3% 9·8% 7·2% 27·7% 11·8% 8·4% 30·4% 12·7% 8·8% 34·7% 15·0% 10·6% 40·1% 18·5% 13·5%
Men 17·6% 6·6% 5·0% 23·3% 9·2% 6·7% 27·9% 11·2% 7·9% 30·9% 12·1% 8·3% 35·3% 14·2% 9·9% 41·1% 17·8% 12·8%
Women 17·9% 7·9% 6·0% 23·3% 10·6% 7·8% 27·4% 12·7% 9·2% 29·8% 13·7% 9·5% 33·9% 16·1% 11·5% 38·8% 19·5% 14·5%
Hodgkin’s disease
All patients 75·6% 56·5% 47·7% 82·7% 66·8% 58·8% 87·6% 75·1% 69·2% 90·0% 80·3% 75·8% 90·8% 82·9% 78·3% 91·4% 85·0% 80·0%
Men 73·9% 54·2% 45·2% 82·2% 65·1% 56·5% 87·5% 74·6% 68·7% 89·7% 80·4% 75·8% 90·3% 82·5% 77·2% 90·8% 84·1% 77·7%
Women 77·8% 59·4% 51·0% 83·3% 69·2% 61·8% 87·7% 75·8% 69·9% 90·3% 80·2% 75·8% 91·4% 83·4% 79·7% 92·3% 86·3% 83·1%
Non-Hodgkin lym phoma
All patients 49·5% 29·9% 22·0% 58·8% 37·5% 28·1% 65·8% 44·9% 35·2% 70·1% 52·3% 43·9% 74·3% 59·7% 52·6% 79·6% 68·8% 63·1%
Men 49·4% 29·3% 21·7% 58·6% 36·8% 27·6% 65·7% 44·2% 34·5% 70·0% 51·6% 43·4% 74·4% 59·1% 51·9% 79·8% 68·1% 62·2%
Women 49·6% 30·6% 22·3% 59·0% 38·4% 28·8% 66·0% 45·8% 35·9% 70·2% 53·2% 44·6% 74·3% 60·5% 53·3% 79·4% 69·5% 64·1%
Multiple myeloma
All patients 37·4% 11·8% 6·2% 48·4% 17·2% 8·6% 57·4% 22·0% 10·8% 64·5% 27·7% 14·3% 70·6% 36·0% 21·4% 76·7% 47·0% 32·6%
Men 36·8% 12·1% 6·8% 47·8% 17·2% 9·0% 57·4% 22·2% 11·1% 65·7% 28·8% 15·1% 71·8% 37·9% 23·5% 78·0% 50·0% 36·8%
Women 38·0% 11·4% 5·5% 49·0% 17·1% 8·1% 57·3% 21·8% 10·3% 63·2% 26·4% 13·4% 69·3% 34·0% 19·2% 75·3% 43·8% 27·9%
Leu kaemia
All patients 34·2% 13·1% 6·9% 47·3% 23·6% 14·9% 57·8% 34·0% 24·0% 63·8% 41·6% 32·3% 66·3% 46·4% 38·7% 68·6% 51·5% 46·1%
Men 35·4% 13·1% 6·6% 48·6% 23·7% 14·4% 59·4% 34·4% 23·6% 65·6% 42·4% 32·3% 68·3% 47·7% 39·4% 70·7% 53·3% 47·6%
Women 32·5% 13·0% 7·2% 45·6% 23·5% 15·6% 55·8% 33·6% 24·6% 61·4% 40·5% 32·2% 63·7% 44·6% 37·8% 65·9% 49·1% 44·2%
Other cancers*
All patients 55·3% 38·4% 34·8% 54·7% 36·5% 32·0% 54·5% 35·2% 30·2% 56·6% 37·1% 32·5% 59·7% 40·6% 36·6% 63·5% 45·2% 41·9%
Men 57·3% 40·4% 36·9% 54·3% 35·2% 30·7% 52·6% 31·9% 26·9% 55·0% 33·7% 29·2% 58·7% 37·8% 33·9% 63·1% 43·3% 40·1%
Women 53·0% 36·2% 32·5% 55·2% 37·9% 33·4% 56·6% 39·0% 33·9% 58·4% 41·0% 36·3% 60·9% 43·9% 39·7% 63·9% 47·5% 44·0%
*Other cancers: all other malignant tumours are combined; they also include laryngeal cancer in women and breast cancer in men.
Table 2: 40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults (15–99 years) in England from 1971 to 2011 and trends in the 
age-adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex
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1971–72 1980–81 1990–91 2000–01 2005–06 2010–11 (prediction)
1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years
All cancers combined
All patients 48·1% 28·9% 23·4% 53·6% 34·7% 28·9% 58·4% 40·4% 34·6% 63·2% 46·9% 41·6% 66·3% 50·6% 46·0% 69·4% 54·2% 50·2%
Men 42·9% 24·8% 20·4% 48·2% 28·8% 23·7% 53·2% 33·9% 28·1% 59·1% 41·5% 35·9% 62·7% 45·7% 41·0% 65·9% 49·2% 45·5%
Women 53·2% 32·9% 26·3% 58·9% 40·5% 34·1% 63·4% 46·8% 41·1% 67·2% 52·2% 47·2% 69·9% 55·5% 51·0% 72·8% 59·0% 54·8%
Oesophagus
All patients 16·9% 5·2% 4·1% 18·7% 6·0% 5·2% 22·8% 6·9% 5·8% 30·7% 8·8% 6·7% 35·5% 10·6% 7·9% 39·7% 12·9% 9·5%
Men 17·9% 5·1% 3·8% 19·1% 5·8% 4·9% 23·2% 7·0% 6·0% 32·8% 9·3% 7·1% 37·7% 10·9% 7·8% 42·3% 12·7% 8·7%
Women 15·2% 5·4% 4·8% 18·1% 6·4% 5·6% 22·1% 6·8% 5·5% 27·4% 7·9% 6·1% 32·1% 10·3% 8·0% 35·8% 13·3% 10·8%
Stomach
All patients 15·2% 5·7% 4·6% 21·3% 10·1% 8·9% 24·7% 10·8% 9·2% 30·9% 12·6% 9·9% 36·5% 15·5% 12·0% 43·1% 19·5% 14·9%
Men 15·3% 5·6% 4·5% 21·0% 9·7% 8·6% 25·0% 10·6% 9·1% 32·3% 12·6% 9·9% 38·2% 15·5% 11·7% 45·0% 19·4% 14·4%
Women 15·0% 6·0% 4·9% 21·9% 10·8% 9·4% 24·1% 11·2% 9·3% 28·5% 12·7% 10·1% 33·5% 15·6% 12·4% 39·6% 19·6% 16·0%
Colon
All patients 42·7% 25·0% 22·8% 51·8% 33·3% 30·9% 58·4% 39·8% 37·2% 63·2% 45·2% 42·4% 67·8% 50·9% 48·3% 73·0% 57·7% 55·4%
Men 43·1% 26·5% 24·5% 51·9% 33·3% 30·9% 60·0% 40·3% 37·4% 65·8% 46·6% 43·3% 70·2% 51·8% 48·5% 74·9% 57·9% 54·9%
Women 42·2% 23·4% 21·2% 51·8% 33·3% 31·0% 56·9% 39·2% 37·0% 60·5% 43·7% 41·6% 65·4% 49·9% 48·0% 71·1% 57·5% 55·8%
Rectum
All patients 50·8% 22·9% 19·7% 58·5% 31·2% 27·7% 65·7% 40·6% 37·1% 72·4% 50·0% 46·7% 75·2% 54·4% 51·3% 77·7% 58·5% 55·6%
Men 50·6% 21·4% 17·9% 58·7% 29·9% 26·1% 66·5% 39·8% 35·9% 73·2% 49·5% 45·8% 76·1% 54·1% 50·6% 78·6% 58·4% 55·1%
Women 51·0% 25·2% 22·1% 58·1% 33·1% 30·0% 64·6% 41·7% 38·9% 71·4% 50·8% 48·0% 74·0% 54·8% 52·3% 76·4% 58·6% 56·4%
Pancreas
All patients 12·2% 3·8% 2·4% 12·8% 4·6% 3·4% 12·9% 4·2% 2·8% 14·0% 3·0% 1·5% 16·3% 3·0% 1·3% 19·0% 3·3% 1·2%
Men 11·5% 4·0% 2·7% 13·0% 5·6% 4·6% 13·5% 5·0% 3·7% 14·8% 3·4% 1·8% 16·7% 3·4% 1·5% 19·4% 3·7% 1·4%
Women 12·9% 3·7% 2·1% 12·5% 3·7% 2·3% 12·4% 3·3% 2·0% 13·3% 2·6% 1·3% 15·8% 2·7% 1·2% 18·6% 2·9% 1·1%
Larynx
Men 77·7% 56·3% 45·9% 82·5% 64·8% 55·6% 82·1% 63·9% 54·5% 80·2% 60·4% 50·4% 81·4% 63·3% 53·7% 84·0% 68·1% 59·5%
Lung
All patients 15·6% 5·1% 3·6% 18·7% 7·2% 5·5% 19·7% 6·8% 4·7% 21·5% 5·9% 3·3% 25·5% 6·9% 3·6% 31·1% 8·6% 4·2%
Men 14·6% 4·2% 2·8% 18·6% 7·2% 5·6% 19·5% 6·7% 4·6% 21·1% 5·5% 2·9% 24·4% 6·3% 3·1% 28·8% 7·7% 3·7%
Women 17·4% 6·6% 5·1% 18·8% 7·0% 5·3% 20·1% 6·9% 4·9% 22·2% 6·6% 4·0% 27·4% 8·0% 4·3% 35·2% 10·3% 5·1%
Melanoma of skin
All patients 79·9% 51·1% 44·0% 82·3% 63·1% 57·2% 85·6% 71·4% 66·3% 91·3% 77·5% 72·9% 94·4% 82·4% 77·6% 96·8% 89·0% 82·1%
Men 73·8% 38·9% 33·3% 76·6% 51·0% 44·6% 81·8% 62·5% 55·9% 89·4% 71·0% 65·8% 93·1% 76·4% 68·9% 95·8% 83·7% 68·3%
Women 84·4% 60·1% 52·0% 86·5% 72·0% 66·6% 88·3% 78·0% 73·9% 92·7% 82·2% 78·1% 95·3% 86·7% 84·1% 97·6% 92·9% 92·2%
Breast
Women 74·9% 47·9% 34·8% 81·8% 60·3% 48·5% 87·4% 71·7% 62·3% 91·4% 80·4% 73·4% 93·0% 83·8% 77·9% 94·3% 86·7% 81·8%
Cervix
Women 73·9% 52·8% 47·4% 80·0% 63·2% 57·8% 78·6% 59·9% 55·0% 78·5% 59·9% 55·2% 79·7% 62·4% 57·5% 81·7% 65·6% 60·3%
Uterus
Women 72·7% 55·9% 53·4% 76·2% 61·7% 56·8% 80·6% 67·0% 62·2% 85·3% 72·4% 69·6% 88·1% 76·8% 73·9% 90·5% 81·2% 77·8%
Ovary
Women 48·2% 22·2% 18·0% 52·0% 26·2% 21·8% 56·9% 31·4% 26·6% 61·1% 36·6% 31·8% 63·1% 39·2% 34·4% 65·1% 41·9% 37·1%
Prostate
Men 62·7% 36·6% 27·8% 65·9% 35·9% 25·6% 72·9% 44·6% 32·9% 85·0% 68·8% 59·1% 90·1% 79·8% 74·9% 93·7% 87·1% 87·1%
Testis
Men 82·9% 69·5% 66·2% 89·9% 81·1% 80·0% 94·4% 89·7% 89·1% 97·1% 95·0% 94·1% 97·4% 96·0% 94·4% 97·4% 96·6% 93·9%
Kidney
All patients 43·7% 29·0% 24·4% 46·9% 31·0% 25·1% 53·0% 36·5% 29·7% 61·6% 46·2% 39·5% 66·6% 51·2% 44·0% 70·8% 55·2% 47·3%
Men 44·8% 30·6% 25·3% 48·5% 32·0% 25·6% 54·6% 37·2% 30·0% 62·3% 46·9% 39·9% 67·6% 51·4% 43·5% 72·2% 53·9% 44·2%
Women 41·9% 26·4% 22·9% 44·2% 29·5% 24·4% 50·3% 35·4% 29·2% 60·5% 45·1% 38·7% 64·8% 50·8% 44·8% 68·5% 57·3% 52·4%
(Table 3 continues on next page)
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46% at 10 years. Both the levels and the trends in the all-
cancers survival index were similar in England and 
Wales. The average absolute diﬀ erence between the two 
countries was less than 1% (ﬁ gure 1, tables 2 and 3).
Survival for both sexes combined varied widely for 
diﬀ erent cancers, with the most recent predicted 10-year 
net survival adjusted for age and sex ranging from only 
1·1% for pancreatic cancer to 98·2% for testicular cancer. 
A scatter-plot of the 1-year, 5-year, and 10-year survival 
estimates for adults diagnosed in 2010–11 against the 
absolute change since 1971 enables three broad clusters 
of cancers to be identiﬁ ed (ﬁ gure 2). The ﬁ rst cluster 
consists of cancers with high survival in 2010–11 for 
which the absolute increase in survival since 1971–72 is 
progressively larger for survival at 1, 5, and 10 years. It 
includes cancers of the breast, prostate, testis, and 
uterus, and melanoma and Hodgkin’s disease.
The second cluster is of cancers with a moderate level of 
survival (64–84%) in 2010–11 and, generally, smaller 
increases since 1971–72. This cluster consists of cancers of 
the larynx, cervix, rectum, colon, bladder, ovary, and 
kidney, with non-Hodgkin lymphoma, multiple myeloma, 
and leukaemia. For multiple myeloma and leukaemia, 
age-adjusted 10-year survival rose by more than 22% 
between the periods 1990–91 and 2010–11, from around 
10·8% to a predicted 32·6% for multiple myeloma and 
from 24·0% to 46·1% for leukaemia (table 2).
The third cluster is of cancers for which survival for 
patients diagnosed during 2010–11 is still low, and for 
which little or no improvement has occurred in the past 
40 years: this group consists of malignancies of the brain, 
stomach, lung, oesophagus, and pancreas.
This clustering can be seen as early as 1 year after 
diagnosis, and each cancer is in the same cluster, 
irrespective of the time since diagnosis (and the nation). 
We observed the largest absolute change in the age-
adjusted survival for multiple myeloma, leukaemia, and 
prostate cancer.
1971–72 1980–81 1990–91 2000–01 2005–06 2010–11 (prediction)
1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years 1 year 5 years 10 years
(Continued from previous page)
Bladder
All patients 53·8% 37·4% 33·9% 66·3% 49·1% 42·5% 77·1% 61·5% 53·5% 81·4% 67·6% 61·6% 78·0% 63·7% 60·6% 70·5% 55·5% 56·8%
Men 56·1% 38·0% 34·1% 69·5% 51·5% 44·6% 80·3% 64·6% 56·3% 85·0% 71·0% 64·8% 81·8% 66·7% 63·7% 74·5% 57·9% 59·9%
Women 47·9% 35·8% 33·4% 58·0% 43·1% 37·3% 68·9% 53·7% 46·2% 72·2% 58·9% 53·6% 68·3% 56·0% 52·8% 60·1% 49·1% 48·8%
Brain
All patients 24·4% 10·7% 7·9% 26·7% 11·8% 8·9% 29·0% 12·8% 9·6% 33·1% 14·8% 10·6% 36·8% 16·5% 11·4% 40·1% 18·0% 12·0%
Men 24·5% 10·3% 7·7% 26·6% 11·5% 8·7% 28·3% 11·9% 8·8% 32·7% 13·5% 9·1% 36·9% 15·6% 10·3% 40·8% 17·5% 11·2%
Women 24·4% 11·1% 8·2% 26·7% 12·3% 9·1% 29·9% 14·2% 10·8% 33·7% 16·6% 12·7% 36·6% 17·7% 13·0% 39·2% 18·6% 13·1%
Hodgkin’s disease
All patients 72·1% 52·1% 43·1% 78·2% 62·0% 54·0% 84·4% 72·0% 65·4% 87·6% 78·5% 73·2% 89·7% 81·5% 76·8% 92·3% 85·7% 81·8%
Men 74·5% 54·8% 44·5% 79·1% 62·9% 53·7% 85·1% 73·0% 65·6% 87·4% 78·3% 72·2% 89·6% 81·6% 76·2% 92·3% 85·6% 81·0%
Women 68·9% 48·6% 41·2% 77·0% 60·9% 54·4% 83·5% 70·7% 65·2% 87·9% 78·7% 74·6% 89·8% 81·4% 77·7% 92·4% 85·8% 82·8%
Non-Hodgkin lymphoma
All patients 50·2% 31·1% 23·8% 54·7% 33·8% 25·4% 61·0% 39·8% 30·8% 68·6% 50·7% 41·9% 73·7% 58·3% 50·3% 79·3% 66·7% 59·7%
Men 51·8% 30·8% 22·1% 54·2% 33·4% 24·2% 60·0% 39·7% 30·0% 68·9% 50·9% 41·3% 74·0% 57·9% 48·7% 79·0% 65·1% 56·8%
Women 48·3% 31·5% 25·9% 55·3% 34·2% 26·7% 62·2% 40·0% 31·7% 68·4% 50·4% 42·7% 73·4% 58·8% 52·0% 79·6% 68·5% 63·1%
Multiple myeloma
All patients 34·1% 12·6% 8·0% 49·1% 19·9% 11·9% 57·8% 24·1% 13·5% 62·7% 26·9% 14·0% 67·6% 33·6% 19·0% 73·8% 44·5% 28·7%
Men 33·2% 14·0% 10·7% 48·6% 20·0% 12·7% 58·3% 24·3% 13·8% 64·8% 28·8% 15·9% 70·0% 35·8% 20·9% 76·2% 46·7% 30·2%
Women 35·2% 11·1% 5·1% 49·7% 19·8% 11·0% 57·2% 23·9% 13·1% 60·4% 24·7% 11·9% 64·9% 31·2% 16·8% 71·0% 42·0% 27·0%
Leukaemia
All patients 30·2% 11·0% 6·1% 43·5% 21·2% 14·1% 55·4% 33·0% 24·5% 64·9% 43·6% 34·1% 69·1% 49·5% 40·5% 72·9% 55·6% 47·7%
Men 27·7% 8·7 3·9% 43·5% 20·2% 12·8% 57·0% 33·1% 24·0% 66·5% 43·3% 32·5% 70·4% 49·4% 39·4% 74·3% 56·2% 47·9%
Women 33·4% 14·0% 8·9% 43·5% 22·4% 15·6% 53·4% 32·7% 25·1% 62·9% 44·0% 36·2% 67·5% 49·7% 42·0% 71·0% 54·7% 47·4%
Other cancers*
All patients 53·9% 37·6% 33·7% 55·7% 39·3% 34·9% 55·8% 38·9% 34·1% 55·9% 38·3% 33·4% 58·9% 41·1% 36·1% 62·9% 45·2% 40·3%
Men 56·4% 40·2% 36·3% 56·4% 39·8% 35·1% 55·2% 37·5% 32·6% 54·6% 35·5% 30·7% 58·5% 38·9% 33·8% 64·1% 44·3% 38·6%
Women 51·1% 34·7% 30·7% 54·8% 38·7% 34·6% 56·5% 40·5% 35·9% 57·4% 41·4% 36·4% 59·3% 43·6% 38·9% 61·5% 46·4% 42·2%
*Other cancers: all other malignant tumours are combined; they also include laryngeal cancer in women and breast cancer in men
Table 3: 40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults (15–99 years) in Wales from 1971 to 2011 and trends in the 
age-adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex
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1-year survival from lung cancer has improved 
substantially, from 16% in 1971–72 to 32% in 2010–11. 
However, estimated long-term survival for patients 
diagnosed in 2010–11 is very poor for both sexes: as low 
as 10% at 5 years and 4% and 7% in men and women, 
respectively, at 10 years. This overall pattern of no 
improvement in long-term survival is common in the 
cluster of poor-prognosis cancers (oesophagus, stomach, 
pancreas, and brain), for men and women and for both 
England and Wales.
Survival for breast cancer has seen a rapid and 
substantial improvement during the past 40 years. 5-year 
survival increased from 53% in 1971–72 to a predicted 
value of 87% in 2010–11. After 10 years, survival rose from 
40% in 1971–72 to a predicted 78% for patients diagnosed 
during 2010–11. Diﬀ erences between 5-year and 10-year 
survival estimates remained broadly constant since 1971, 
showing that most of the improvements in long-term 
survival arose in the ﬁ rst 5 years after diagnosis. Breast 
cancer accounted for nearly a third of all cancers in 
women, which partly explains the higher all-cancers 
survival index in women than in men.
Although survival from cancers of the colon and 
rectum is much lower than survival from breast cancer 
(around 20% lower in 2010–11), the trends in 1-year, 
5-year, and 10-year survival for these two cancers have 
followed an almost identical pattern to that of breast 
cancer during the past 40 years.
For men diagnosed with prostate cancer during 
2010–11, the predicted values for 5-year and 10-year 
estimates are almost identical at 85% and 84%, 
respectively, which are huge increases from the values of 
37% and 25% for men diagnosed 40 years ago. The trends 
are quite distinct for short-term, medium-term, and 
long-term survival. In both England and Wales, 1-year 
survival has been increasing since 1971–72, whereas 
acceleration in 5-year survival started for men diagnosed 
in the 1980s; 10-year survival only began increasing for 
men diagnosed in the 1990s.
For women diagnosed with cancer of the ovary during 
2010–11, the age-adjusted survival was predicted as 46% 
at 5 years and 35% at 10 years compared with 20% and 
18%, respectively, for women diagnosed during 1971–72. 
These results suggest that the underlying increase in 
survival of up to 5 years is likely to continue.
Net survival is generally lower for the oldest patients 
(75–99 years) than the youngest (15–44 years), even 
though net survival accounts for a higher mortality from 
causes other than cancer in elderly patients. This ﬁ nding 
is shown by a scatter-plot of the age gap in net survival at 
1, 5, and 10 years after diagnosis for adults diagnosed in 
Figure 2: Net survival adjusted for age and sex for each cancer in 2010–11, 
and absolute change* since 1971, all adults (15–99 years), England and 
Wales: 1, 5, and 10 years after diagnosis
*The absolute change is the simple arithmetic diﬀ erence between net survival in 
2010–11 and the survival in 1971–72. NHL=non-Hodgkin lymphoma.
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2010–11 against the absolute change since 1971–72: it 
shows a negative gap in survival for most cancers (y-axis 
of ﬁ gures 3 and 4).
The largest age gaps in survival in men were observed 
for cancers for which high-dose chemotherapy is the key 
treatment (lymphoma, multiple myeloma, and leukaemia), 
but we could not identify any overall temporal patterns. 
For women, the largest age gaps were noted for brain 
tumours, and cancers of the ovary and cervix, and multiple 
myeloma, but the clustering was less obvious than in men. 
The age gap tended to narrow for melanoma and cancer of 
the uterus in women but widened for long-term survival of 
ovarian cancer.
Discussion
The index of net survival for all cancers combined has 
increased substantially: for patients diagnosed in 1971–72, 
the index was 50% at 1 year after diagnosis. Our 
prediction is that, for patients diagnosed during 2010–11, 
the all-cancers survival index will reach 50% at 10 years 
after diagnosis. Very similar patterns of change and 
levels of survival were noted in both England and Wales.
Survival has increased steadily during the 40 years 
since 1971, with a slight acceleration in the past 
10–15 years, particularly for 5-year and 10-year survival, in 
both England and Wales. After implementation of the 
NHS cancer plan for England,19 we reported a slight 
acceleration in the 1-year cancer survival trends during 
2004–06, by contrast with Wales,2 where a national cancer 
plan was only introduced in 2006. The pattern was not so 
clear for survival at 3 years after diagnosis. The ﬁ ndings 
reported here suggest a continuing acceleration of these 
trends for longer-term survival between 2005–06 and 
2010–11 in England, but also in Wales (panel).
The completeness and quality of cancer registration 
and follow-up data in both England and Wales have been 
systematically assessed and are thought to be very high 
throughout the period 1971–2011, despite undeniable 
improvement during the 1970s–80s.21–23 This improvement 
cannot explain long-term trends in cancer survival.24,25 
Furthermore, with the exception of bladder cancer, overall 
changes in disease deﬁ nitions are limited, even for 
haemopoietic malignancies. To aﬀ ect the survival index, 
such a change in disease deﬁ nition would need to aﬀ ect a 
substantial proportion of all cancers, for which prognosis 
would also need to be very diﬀ erent from that for other 
cancers. These conditions are not met.
In some strata deﬁ ned by age, sex, cancer, and calendar 
period of diagnosis, especially in Wales, few deaths 
Figure 3: Age gap* in net survival by cancer, men (15–99 years) diagnosed 
during 2010–11 versus absolute change† in the age gap since 1971, England 
and Wales: 1, 5, and 10 years after diagnosis
*The age gap represents the absolute diﬀ erence (%) between net survival in the 
oldest (75–99 years) and youngest (15–45 years) groups of patients; a negative 
value means that survival is lower in the oldest group than the youngest group. 
†The absolute change is the simple arithmetic diﬀ erence between the age gap in 
2010–11 and the age gap in 1971–72. NHL=non-Hodgkin lymphoma.
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occurred. To obtain more stable net survival estimates, we 
therefore estimated net survival using a modelling 
approach rather than the non-parametric Pohar-Perme 
approach.20
The index of net survival for all cancers combined 
provides one convenient number that summarises the 
overall patterns of cancer survival in any one population 
or country, in each calendar period for young and old men 
and women and for a wide range of cancers with very 
disparate survival. The index is unaﬀ ected by changes in 
the proportion of cancers of diﬀ erent lethality in either 
sex, such as the reduction of lung cancer or the increase in 
prostate cancer in men. Similarly, the index is unaﬀ ected 
by ageing of the population of patients with cancer or 
shifts in the proportion of any cancer between men and 
women. The value of the index changes only when survival 
for one or more cancers changes, for one or more age 
groups. The index therefore shows overall progress in 
cancer management, whether from earlier diagnosis, or 
earlier stage of disease, or improved treatment and care.
However, the all-cancers survival index needs careful 
interpretation: for example, the predicted value of 50% for 
the 10-year all-cancers survival index for 2010–11 does not 
mean that half of all patients will be cured or “beat cancer”, 
as has been portrayed in the media.26 The index is designed 
as a public health measure that summarises cancer 
survival trends in an entire population, to help to assess 
progress in the overall eﬀ ectiveness of the health system in 
diagnosis and management of patients with cancer. The 
index does not reﬂ ect the prospects of survival for any 
individual patients with cancer. The index is based on net 
survival, which is an unbiased measure of population-
based survival from cancer after adjustment for other 
causes of death. Net survival is the most valid available 
metric for comparison of survival between populations 
and for assessment of progress in cancer survival over 
time. The all-cancers net survival index should nevertheless 
be interpreted in conjunction with other information 
available in the population or country for which the index 
has been prepared. It should be seen as a guide to raise 
questions about the potential for improvement.
The average 10% diﬀ erence in the survival index 
between men and women has been a consistent feature 
for 40 years. It arises because, for several individual 
cancers, survival is slightly higher for women, but mostly 
because the cancers that are most common in women, 
such as breast cancer (weight of 0·31 in the survival index 
for women), generally have higher survival than the 
cancers that are most common in men, such as lung 
Figure 4: Age gap* in net survival by cancer, women (15–99 years) diagnosed 
during 2010–11 versus absolute change† (%) in the age gap since 1971, 
England and Wales: 1, 5, and 10 years after diagnosis
*The age gap represents the absolute diﬀ erence (%) between net survival in the 
oldest (75–99 years) and youngest (15–45 years) groups of patients; a negative 
value means that survival is lower in the oldest group than the youngest group. 
†The absolute change is the simple arithmetic diﬀ erence between the age gap in 
2010–11 and the age gap in 1971–72. NHL=non-Hodgkin lymphoma.
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cancer (weight of 0·22 in the index for men). The slight 
narrowing in the sex gap observed in the most recent 
periods might be explained by the rapid increase in 
survival for prostate cancer (weight of 0·19 in the index for 
men), particularly at 5 and 10 years after diagnosis. This 
rapid increase in survival for prostate cancer has been 
largely attributed to the widespread use of prostate-speciﬁ c 
antigen (PSA) testing, resulting in the diagnosis of many 
less advanced tumours with a shift of the stage distribution 
to less advanced and less aggressive disease. However, 
importantly, survival had already started to increase, albeit 
more slowly, much before PSA testing was widely used.27 
The more recent increase in long-term survival suggests 
that this improvement is not simply because of a shift in 
the stage distribution after increasingly wide use of the 
PSA test. The increase in short-term survival, which began 
as early as the 1970s, and the increase in 5-year survival in 
the 1980s and then in the 10-year survival in the following 
decade cannot simply be attributed to PSA.
We were able to group the 21 most common cancers 
into three clusters on the basis of their survival. Despite 
some large gains in survival, these clusters are, with few 
exceptions, the same in 2011 as in 1971 (data not shown). 
The clusters are identiﬁ able as early as 1 year after 
diagnosis, and they are consistent at 5 and 10 years after 
diagnosis, both in England and Wales.
Cluster 1 includes cancers with a good prognosis: 
survival is now very high, after a large increase since 
1971, particularly at 5 and 10 years after diagnosis. 1-year 
survival seems to have reached a ceiling for most of these 
cancers, but survival at 5 and 10 years is still much lower 
than at 1 year for breast cancer and Hodgkin’s disease. 
The absence of any plateau in survival, even 10 years after 
diagnosis, shows that cure at the population level has still 
not been reached for these cancers, leaving room for 
substantial further improvement in long-term survival.
For most cancers in the other two clusters, survival at 5 
and 10 years after diagnosis is still much lower than 
1-year survival. The second cluster consists of a further 
mix of cancers for which either survival has remained 
moderate since the early 1970s, or moderate levels of 
survival in 2011 are the result of large improvements 
during the past 40 years. The second situation is well 
illustrated by the steep increase in survival from multiple 
myeloma since 2000–01, probably explained by the 
introduction of higher-dose treatment regimens around 
2000. For the cancers in this cluster that have shown no 
evidence of improvement, eﬀ orts should be made to 
achieve earlier diagnosis, and to focus on stricter 
guidelines for improved treatment, such as increased use 
of surgery, radiotherapy with curative intent, neoadjuvant 
therapies, or a combination of the three.
The eﬀ ect of mass-screening on survival varies with the 
cancer. For cervical cancer, an eﬃ  cient screening 
programme does not necessarily lead to an improvement 
in survival because screening prevents the occurrence of 
invasive tumours, thereby reducing incidence, and the 
remaining patients are, on average, diagnosed with more 
advanced disease.28 A quasi-plateau in 1-year survival has 
been observed since 2000–01 (appendix 1 and 2).
By contrast, breast cancer screening aims to diagnose 
the disease at an early stage, rather than to prevent it. Its 
real eﬀ ect on survival has been questioned mainly because 
of possible overdiagnosis and lead time. However, 
overdiagnosis does not exceed a few percent,29 and the 
advantage in survival remains important for screen-
detected breast cancer after accounting for lead time.30 
Improvement in breast cancer survival has been large 
because of both early diagnosis and improved treatment, 
although net survival continues to decrease even 10 years 
after diagnosis, showing late recurrences. The age gap in 
survival has also decreased, supporting more rapid 
improvement in survival for older women (and for the 
screened age group) than in younger women.31
Screening for colorectal cancer, which started in 2006, 
aims to prevent invasive malignant tumours (by 
removing polyps with adenoma tous change) and to 
diagnose cancer at an early stage. Therefore, although it 
is too recent to have any eﬀ ect on these results, lessons 
from both cervical and breast cancer screening 
See Online for appendix
Panel: Research in context
Systematic review
Health policy measures to improve the organisation and 
delivery of services for the prevention, diagnosis, and 
treatment of cancer should be based on sound evidence. 
Population-based survival trends have proved to be a key 
metric for the overall eﬀ ectiveness of health systems. An 
unbiased estimator of net survival was introduced in 2012.20 
We have not undertaken a literature review, but so far, only a 
few countries have published population-based cancer 
survival using this estimator, including in England by our 
research group.12 No other country has constructed a single, 
summary index of net survival for all cancers combined. 
A simple, robust, one-number index of net survival for all 
cancers combined can contribute to the evidence base for 
rational health policy. 
Interpretation
Changes in the net survival index reﬂ ect changes in survival 
for one or more cancers, not simply changes in the 
distribution of cancer patients by age, cancer site, or sex. The 
net survival index increased substantially between 1971 and 
2011, representing a substantial gain in overall survival from 
all cancers combined. Net survival varied widely for diﬀ erent 
cancers, and was generally lower for older patients than 
younger patients, even after adjustment for the higher 
mortality from other causes in older patients. Three clusters 
of cancers, with high, moderate, and low survival, can be 
distinguished as early as 1 year after diagnosis. Overall, the 
survival trends are encouraging in both England and Wales, 
but they also suggest strongly the need for renewed eﬀ orts to 
achieve better outcomes.
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programmes will also help us to monitor the eﬀ ect of 
screening on the prognosis of colorectal cancer.
A wide age gap in survival was still present for most 
cancers in 2010–11. Some of these diﬀ erences are related 
to screening or early diagnostic practices (breast, cervix, 
prostate). Also, the disease, and its prognosis, might 
radically diﬀ er by age, such as leukaemia: the treatment 
of acute disease in young patients improved 
substantially, by contrast with chronic leukaemia in 
elderly patients, but separation of both diseases is not 
possible over the entire period 1971–2011. However, in 
other countries, the age gap in cancer survival is much 
narrower than in England and Wales.32,33 The wide age-
related inequalities in cancer survival in England and 
Wales are thus likely to be avoidable. They could be 
substantially reduced.
1-year survival has improved substantially for cancers 
with a particularly poor prognosis (cluster 3), but longer-
term survival (5 and 10 years after diagnosis) has hardly 
changed during the past four decades. Among these 
cancers, substantial improvements should be achievable 
for lung cancer: in 2011, National Institute for Health and 
Care Excellence (NICE) guidelines34 underlined the need 
for improved staging and increased widespread access to 
surgery and radiotherapy with curative intent for non-
small-cell lung cancer. Adherence to these guidelines 
and their eﬀ ect on cancer outcomes has not yet been 
exhaustively assessed.35
In summary, despite impressive overall improvements 
in cancer survival during the past 40 years in both 
England and Wales, the wide and persistent diﬀ erences 
in survival between cancers, together with the wide and 
persistent age gap in survival for most cancers, suggest 
the need for renewed eﬀ orts to achieve improved 
outcomes, particularly in elderly patients. The ﬁ ndings 
reported here oﬀ er clues for focused research to dissect 
the underlying causes of these diﬀ erences in cancer 
survival. The results should prompt action to improve 
public health in both England and Wales. This research 
will need systematic linkage of clinical audit streams 
and other detailed data streams to population-based 
cancer registry data, but the recent crisis of public 
concern about the sharing of individual health data for 
conﬁ dential public health research will need to be 
resolved ﬁ rst.36
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